NASDAQ:NVAX - Novavax Stock Price, Forecast & News

Novavax's stock was trading at $10.51 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, NVAX shares have increased by 36.1% and is now trading at $14.30. View which stocks have been mosted impacted by Coronavirus.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novavax in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Novavax.

Novavax is scheduled to release its next quarterly earnings announcement on Thursday, May 7th 2020. View our earnings forecast for Novavax.

Novavax, Inc. (NASDAQ:NVAX) announced its quarterly earnings data on Wednesday, March, 11th. The biopharmaceutical company reported ($1.13) EPS for the quarter, missing the Zacks' consensus estimate of ($1.06) by $0.07. The biopharmaceutical company earned $8.82 million during the quarter, compared to the consensus estimate of $3.99 million. View Novavax's earnings history.

Shares of Novavax reverse split before market open on Friday, May 10th 2019. The 1-20 reverse split was announced on Wednesday, May 8th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 9th 2019. An investor that had 100 shares of Novavax stock prior to the reverse split would have 5 shares after the split.

7 brokers have issued twelve-month price objectives for Novavax's stock. Their forecasts range from $7.00 to $24.00. On average, they anticipate Novavax's share price to reach $18.86 in the next year. This suggests a possible upside of 31.9% from the stock's current price. View analysts' price targets for Novavax.

Media headlines about NVAX stock have been trending very positive recently, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Novavax earned a news impact score of 4.0 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the next several days. View the latest news aboutNovavax.

Some companies that are related to Novavax include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Novavax investors own include Egalet (EGLT), EXACT Sciences (EXAS), Palo Alto Networks (PANW), Akebia Therapeutics (AKBA), TG Therapeutics (TGTX), Cara Therapeutics (CARA), Gilead Sciences (GILD), Trevena (TRVN), Opko Health (OPK) and Inovio Pharmaceuticals (INO).

Novavax trades on the NASDAQ under the ticker symbol "NVAX."

Novavax's stock is owned by many different institutional and retail investors. Top institutional shareholders include State Street Corp (1.33%), Charles Schwab Investment Management Inc. (0.46%), Bank of New York Mellon Corp (0.40%), TSP Capital Management Group LLC (0.39%), Nuveen Asset Management LLC (0.26%) and Ladenburg Thalmann Financial Services Inc. (0.14%). Company insiders that own Novavax stock include Gregory M Glenn, John A Herrmann III, John Trizzino, Michael A Mcmanus Jr, Rachel K King and Stanley C Erck. View institutional ownership trends for Novavax.

NVAX stock was sold by a variety of institutional investors in the last quarter, including Creative Planning, Bank of America Corp DE, Nuveen Asset Management LLC, Virtu Financial LLC, Bank of New York Mellon Corp, Goldman Sachs Group Inc., Sargent Investment Group LLC, and Sargent Investment Group LLC. Company insiders that have sold Novavax company stock in the last year include Gregory M Glenn, John A Herrmann III, John Trizzino, and Michael A Mcmanus Jr. View insider buying and selling activity for Novavax.

NVAX stock was acquired by a variety of institutional investors in the last quarter, including TSP Capital Management Group LLC, Ikarian Capital LLC, UBS Group AG, Raymond James & Associates, Ladenburg Thalmann Financial Services Inc., Charles Schwab Investment Management Inc., Barclays PLC, and State Street Corp. Company insiders that have bought Novavax stock in the last two years include Gregory M Glenn, John Trizzino, Rachel K King, and Stanley C Erck. View insider buying and selling activity for Novavax.

Shares of NVAX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of NVAX stock can currently be purchased for approximately $14.30.

Novavax has a market capitalization of $736.88 million and generates $18.66 million in revenue each year. The biopharmaceutical company earns $-132,690,000.00 in net income (profit) each year or ($5.80) on an earnings per share basis. Novavax employs 373 workers across the globe. View additional information about Novavax.

The official website for Novavax is http://www.novavax.com/.

Novavax's mailing address is 21 FIRSTFIELD ROAD, GAITHERSBURG MD, 20878. The biopharmaceutical company can be reached via phone at 240-268-2000 or via email at [email protected]